Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Excaliber subsidiary merges with VistaGen

Excaliber Enterprises, Ltd. announced today that its wholly-owned subsidiary has merged with VistaGen Therapeutics, Inc., a private biotechnology company focused on stem cell-based drug rescue and drug development. As a result of the Merger, VistaGen is a wholly-owned subsidiary of Excaliber.

17 May 2011

Pernix first quarter net revenues increase 14% to $10.1 million

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the pediatric market, today announced financial results for the first quarter of 2011.

17 May 2011

Super-resolution microscopy technique reveals how and why cell's defenses fail against plague

Researchers at Sandia National Laboratories have developed a super-resolution microscopy technique that is answering long-held questions about exactly how and why a cell's defenses fail against some invaders, such as plague, while successfully fending off others like E.coli.

17 May 2011

GPSA, Sanofi partner to develop and commercialize GBR 500 for inflammatory disease treatment

Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.

17 May 2011

Pacific Biosciences, Mount Sinai collaborate to advance genomic research

Mount Sinai School of Medicine and Pacific Biosciences of California, Inc. announced a bi-coastal collaboration to advance clinical research through the Mount Sinai Institute for Genomics and Multiscale Biology to be led by Eric E. Schadt, Ph.D.

16 May 2011

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Substances produced by living organisms found in nature-so-called "natural products"-have played a critical role in the development of drugs for life-threatening conditions. The anticancer agent Taxol was sourced from a plant, penicillin from a fungus, and a number of recent breakthroughs have resulted in the development and approval of anticancer drugs derived from marine sources such as coral and sponges.

16 May 2011

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Karo Bio AB is organizing a symposium in Stockholm on May 16-17, where key researchers from the industry and the academic community present and discuss the frontier of research in the field of estrogen receptor beta (ER-beta) and its therapeutic applications.

16 May 2011

Global health Product Development Partners consortium select GVK BIO as preferred provider

GVK Biosciences, Asia's leading drug discovery research & development organization announced today that it has been selected as a preferred provider to a consortium of 14 global Product Development Partners (PDPs) for clinical services in Asia. GVK BIO is the only partner that is headquartered in India.

16 May 2011

Scientists discover new class of compounds that selectively block 'serine hydrolases'

Scientists from The Scripps Research Institute have identified a class of compounds that could be a boon to basic research and drug discovery.

16 May 2011

$100,000 needed to analyze '$1,000' genetic data

Advances in technology have almost lifted the curtain on the long-awaited era of the "$1,000 genome" - a time when all the genes that make up a person can be deciphered for about that amount - compared to nearly $1 million a few years ago.

12 May 2011

Conference to discuss process of synaptic plasticity in Alzheimer's disease

Optimal functioning of neural networks is critical to the complex cognitive processes of memory, language, emotion and reasoning that deteriorate in people suffering from Alzheimer's disease.

12 May 2011

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

The University of Manchester, GlaxoSmithKline and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research, a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out with an initial investment of -5M from each partner over a three year period.

From The University of Manchester 12 May 2011

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.

11 May 2011

Merck launches 'Hope Against Hepatitis C' education program

Merck, known as MSD outside the United States and Canada, today announced the launch of Hope Against Hepatitis C, a company initiative to increase awareness, prevention and diagnosis of hepatitis C virus infection.

10 May 2011

Pepscan, Phylogica collaborate for Phylomer peptide lead optimisation

Phylogica Ltd, a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.

10 May 2011

CDRD reaches agreement with University of Calgary, UTI to develop promising drug candidates

The Centre for Drug Research and Development announced today the signing of affiliation agreements with both the University of Calgary and University Technologies International.

6 May 2011

Odyssey Thera receives US patent for application of contextual high-content assays to diverse biological events

Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,935,493, entitled "Protein fragment complementation assays for high-throughput and high-content screening."

5 May 2011

Rockland produces new Anti-NF-κB monoclonal antibody

Rockland Immunochemicals has produced a new Anti-NF-κB monoclonal antibody validated by several assays relevant for discovery including immunofluorescence microscopy, immunohistochemistry, western blotting and ELISA.

5 May 2011

Almac launches six enzyme screening kits

As anticipated, Almac's biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical companies and continued growth of its screening kits offering. Biocatalysis is increasingly recognised as an alternative solution for solving complex chemistry problems due to its rapid implementation, economic benefits and 'green' reputation.

4 May 2011

Techne acquires Tocris Holdings

Techne Corporation announced today that it has acquired 100% ownership of Tocris Holdings Limited and subsidiaries, a leading supplier of reagents for non-clinical life science research.

3 May 2011

Drug Discovery News and Research

Further Reading

Excaliber subsidiary merges with VistaGen

Pernix first quarter net revenues increase 14% to $10.1 million

Super-resolution microscopy technique reveals how and why cell's defenses fail against plague

GPSA, Sanofi partner to develop and commercialize GBR 500 for inflammatory disease treatment

Pacific Biosciences, Mount Sinai collaborate to advance genomic research

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Global health Product Development Partners consortium select GVK BIO as preferred provider

Scientists discover new class of compounds that selectively block 'serine hydrolases'

$100,000 needed to analyze '$1,000' genetic data

Conference to discuss process of synaptic plasticity in Alzheimer's disease

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Merck launches 'Hope Against Hepatitis C' education program

Pepscan, Phylogica collaborate for Phylomer peptide lead optimisation

CDRD reaches agreement with University of Calgary, UTI to develop promising drug candidates

Odyssey Thera receives US patent for application of contextual high-content assays to diverse biological events

Rockland produces new Anti-NF-κB monoclonal antibody

Almac launches six enzyme screening kits

Techne acquires Tocris Holdings

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News